Industry
BJ Bioscience, Inc.
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
Failure Rate
0.0%
0 terminated/withdrawn out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Phase 1
2(100.0%)
2Total
Phase 1(2)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (2)
Showing 2 of 2 trials
NCT04294576Phase 1Unknown
Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors
Role: lead
NCT05115292Phase 1Unknown
A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma
Role: lead
All 2 trials loaded